SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

Sanofi logo
2 weeks ago

Global HCP Marketing Lead

Sanofi

Cambridge, MA (On-site)Full time$179K/yr – $258K/yr
Braze logo
3 weeks ago

Industry Marketing Lead, Media, Entertainment, Sports & Gaming

Braze

San Francisco, CA (Hybrid)Full time$114K/yr – $171K/yr
Braze logo
3 weeks ago

Industry Marketing Lead, Media, Entertainment, Sports & Gaming

Braze

San Francisco, CA (On-site)Full time$114K/yr – $171K/yr
Pilot.com logo
6 weeks ago

Industry Marketing Lead, Accounting Firms

Pilot.com

Austin, TX (On-site)Full time$135K/yr – $210K/yr
Boston Scientific logo
3 months ago

Segment Marketing Lead, Surgical Endoscopy and National Accounts

Boston Scientific

Massachusetts, USA (On-site)Full time$120K/yr – $150K/yr

Find marketing roles you could actually win

5 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media

Find marketing roles you could actually win

5 open roles0

Popular searches:

Growth MarketingHead of MarketingSEO ManagerProduct MarketingPaid MediaBrand Manager
Growth MarketingHead of MarketingPerformance MarketingContent StrategySEO ManagerProduct MarketingDemand GenerationBrand ManagerPaid MediaMarketing AnalyticsCRM ManagerSocial Media
5 jobs
Sanofi logo

Global HCP Marketing Lead

Sanofi

Cambridge, MA (On-site)

$179K/yr - $258K/yrIn-houseFull-timeSenior level8+ years exp.
2 weeks ago
Braze logo

Industry Marketing Lead, Media, Entertainment, Sports & Gaming

Braze

San Francisco, CA (Hybrid)

$114K/yr - $171K/yrIn-houseFull-timeSenior level7+ years exp.
3 weeks ago
Braze logo

Industry Marketing Lead, Media, Entertainment, Sports & Gaming

Braze

San Francisco, CA (On-site)

$114K/yr - $171K/yrIn-houseFull-timeSenior level7+ years exp.
3 weeks ago
Pilot.com logo

Industry Marketing Lead, Accounting Firms

Pilot.com

Austin, TX (On-site)

$135K/yr - $210K/yrIn-houseFull-timeSenior level7+ years exp.
6 weeks ago
Boston Scientific logo

Segment Marketing Lead, Surgical Endoscopy and National Accounts

Boston Scientific

Massachusetts, USA (On-site)

$120K/yr - $150K/yrIn-houseFull-timeSenior level10+ years exp.
3 months ago
Sanofi logo
Sanofi

Global HCP Marketing Lead

Cambridge, MA (On-site)

$179K/yr – $258K/yrSenior Level8+ years expFull time

Posted 2 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the global HCP marketing plan for a rare IgG4-RD therapy, coordinating segmentation, messaging, and omnichannel campaigns while building advisory structures with KOLs and medical societies.

  • Strategy & Messaging: Shape global HCP messaging and multichannel campaigns across prelaunch and launch.
  • Stakeholder Governance: Lead HCP advisory boards and strategic steering committees to align regions and functions.
  • Insights-to-Action: Translate market research and competitive intelligence into practical campaigns and field-ready assets.

Job Description

Responsibilities

  • Strategic Leadership: Develop and lead the global HCP marketing strategy for rilzabrutinib in IgG4-RD across prelaunch and launch phases
  • Define HCP segmentation, targeting, and positioning strategies based on deep understanding of the treatment landscape and customer insights
  • Collaborate with cross-functional teams including Medical Affairs, Market Access, Patient Advocacy, and Commercial Operations to ensure integrated execution
  • Partner with regional and local marketing teams to adapt global strategies for local markets while maintaining brand consistency
  • Disease State Awareness: Design and implement comprehensive disease state awareness campaigns to increase recognition and diagnosis of IgG4-RD among relevant HCP audiences
  • Develop educational content and programs that address knowledge gaps in disease pathophysiology, clinical presentation, and diagnostic criteria
  • Build strategic partnerships with key opinion leaders (KOLs), medical societies, and advocacy organizations to amplify disease awareness efforts
  • Insights Generation & Market Intelligence: Seamlessly collaborate with market research and CI functions to generate deep HCP, competitive, and market insights that inform strategy development
  • Plan, organize, and facilitate HCP Advisory Boards, bringing together key opinion leaders and clinical experts to gather strategic input on disease state, unmet needs, messaging, and marketing approaches
  • Design and lead Strategic Steering Committees (SSCs) to align cross-functional and cross-regional stakeholders on brand strategy and marketing priorities

Requirements

  • Bachelor's degree in Life Sciences, Marketing, Business, or related field; Advanced degree (MBA, PharmD, PhD) preferred
  • 8+ years of pharmaceutical/biotech marketing experience with demonstrated progression of responsibility
  • Proven track record in HCP marketing, preferably in specialty care, rare disease, or immunology/rheumatology therapeutic areas
  • Experience leading prelaunch and launch marketing activities for innovative therapies
  • Strong understanding of omnichannel marketing principles and digital engagement strategies
  • Experience with AI technologies and their application in pharmaceutical marketing
  • Demonstrated experience planning and facilitating advisory boards and/or strategic steering committees
  • Deep knowledge of pharmaceutical regulatory environment and promotional review processes
  • Demonstrated ability to develop strategic marketing plans and translate them into actionable campaigns

Nice-to-have

  • Experience in rare disease or orphan drug marketing
  • Background in immunology, rheumatology, or related therapeutic areas
  • Experience working with KOLs and medical societies
  • Track record of successful disease awareness campaign development
  • Global marketing experience with ability to work across diverse markets and cultures
  • Familiarity with IgG4-RD or related autoimmune conditions

Benefits

  • The opportunity to shape the launch of a potentially transformative therapy for a rare disease with high unmet need
  • A collaborative, innovative culture that values bold thinking and patient-focused solutions
  • Access to cutting-edge technologies and resources to drive marketing excellence
  • Global exposure and the chance to work with world-class colleagues across functions and geographies
  • Competitive compensation and comprehensive benefits package
  • Commitment to diversity, equity, and inclusion
  • Professional development opportunities and career growth within a global biopharmaceutical leader
Sanofi logo

Sanofi

4.0 Glassdoor

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Founded in 2014
Paris, Île-de-France, FRA
90K employees (5,755 in marketing)
www.sanofi.com
82% recommend to a friend
81% CEO approval

Traffic Signals

Monthly Visitors
880.3K
Monthly Google Ads Budget
$28.6K
Traffic Source Mix
Search
51.6%
Direct
33.7%
Referral
7.4%
Social
6.2%
Paid
1%

Headcount Trend

Current headcount: ~90.7K

Marketing Team

Marketing Team Size
4,595 (5% of company)
Median Career Experience
16 years
Median Tenure
4.3 years
Marketing Roles Posted (Last 30 Days)
11

People

Founders / CEO

Catherine Blanchette
Catherine Blanchette
Global Co-Founder, Sanofi Women's Health ERG
At the company for 3 years 7 months

HR / Recruitment

Rohit Joshi
Rohit Joshi
VP, Global Head of Talent Acquisition
At the company for 3 years 8 months
Stephanie Steiff
Stephanie Steiff
Global Head of Talent Acquisition Specialty Care
At the company for 1 year 7 months

Marketing Leadership

Muthu Senthil
Muthu Senthil
Vice President, Global Brand Leader - Multiple Myeloma
At the company for 11 months
Kara Bogart McManus
Kara Bogart McManus
VP, Head of Marketing, US Rare Disease Franchise
At the company for 7 years 1 month
Marita Holstad
Marita Holstad
Vice President | Global Brand Lead | Immunology, Dermatology
At the company for 2 years 5 months
Pankaj Dave
Pankaj Dave
Associate Vice President & Global Brand Lead - Immune-Mediated Hematology Portfolio
At the company for 6 years 7 months

Funding

Total Funding
$7B
Last Raise
$3B
Post IPO Debt, 5 months ago

Funding History

  • Oct 2025
    Post IPO Debt • $3B
  • Jun 2025
    Post IPO Debt • $1.7B
  • Mar 2025
    Post IPO Debt • $1.6B

Recent News

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
Sep 25, 2025 • Immuneering Corporation
Why PepGen Shares Are Trading Higher By 112%; Here Are 20 Stocks Moving Premarket
Sep 25, 2025 • Benzinga.com
Kardigan Advances Late-Stage Portfolio of Personalized Cardiovascular Medicines in Dilated Cardiomyopathy, Acute Severe Hypertension and Calcific Aortic Valve Stenosis
Sep 25, 2025 • BioSpace
Arecor shares soar on US-rooted $11m financing and key drug alliance
Sep 25, 2025 • businessweekly.co.uk
Sanofi boosts its venture arm with a $625 million commitment
Sep 25, 2025 • PharmiWeb
Immuneering Asset Nearly Doubles Overall Survival in Pancreatic Cancer After 9 Months
Sep 25, 2025 • BioSpace
Financings for Sept. 25, 2025
Sep 25, 2025 • BioWorld Financial Watch
TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
Sep 25, 2025 • PR Newswire
Sanofi Ventures seals $625m fund boost amid sharp fall in biotech backing from VCs
Sep 25, 2025 • AltAssets Private Equity News
AbbVie’s Rinvoq Gains Early Traction in Giant Cell Arteritis Market, Expanding Options for Rheumatologists
Sep 25, 2025 • Spherix Global Insights
TL1A Binder Market Set to Expand by 2034 with Key Players Such as Merck, Roche, Teva Pharmaceuticals, Sanofi, and Others Driving Multi-Indication Advancements | DelveInsight
Sep 25, 2025 • PR Newswire UK
Cancer leadership requires more than science
Sep 25, 2025 • Pharma Letter
Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
Sep 24, 2025 • Sanofi Winthrop Industrie
French court orders Sanofi to pay 150.7 million euros for anti-competitive behaviour
Sep 24, 2025 • MarketScreener
Press release: Availability of the Q3 2025 Aide mémoire
Sep 24, 2025 • BioSpace
French court orders Sanofi to pay $177 million for anti-competitive behaviour
Sep 24, 2025 • MarketScreener
Press release: Availability of the Q3 2025 Aide mémoire
Sep 24, 2025 • Sanofi Winthrop Industrie
Opinion: STAT+: Why pharma companies are suddenly pausing investment in the U.K.
Sep 19, 2025 • STAT
Nektar Provides More Data for Dermatitis Drug, but Key Questions Remain Unanswered
Sep 19, 2025 • BioSpace
Regeneron Pharmaceuticals Inc to donate 500 doses of Inmazeb to WHO
Sep 19, 2025 • MarketScreener
Big Pharma’s pullback from the UK could have serious side-effects for Ireland
Sep 18, 2025 • Irish Times
Mexico City, Rio Lead Coalition on Climate-Related Health Action
Sep 18, 2025 • Mexico Business
BMO Brief: Launching Additional Canadian Depositary Receipts, Expanding Its Line-up to Include Heineken, Sanofi and AXA, Societe Generale; Rheinmetall AG
Sep 18, 2025 • MarketScreener
BMO Launches Additional Canadian Depositary Receipts (CDRs), Expanding Its Line-up to Include Heineken, Sanofi and AXA Français
Sep 18, 2025 • Canada NewsWire
Medley draws interest from Brazil’s pharma giants
Sep 17, 2025 • valorinternational
Sanofi’s brivekimig achieved positive results in hidradenitis suppurative
Sep 17, 2025 • Pharma Letter
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sep 17, 2025 • Sanofi Winthrop Industrie
Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sep 17, 2025 • BioSpace
AllRock Bio: $50 Million Series A Raised For Advancing Lead Clinical Program For Pulmonary Hypertension
Sep 17, 2025 • Pulse 2.0
AstraZeneca says Fasenra misses main goal in COPD trial
Sep 17, 2025 • Investing.com
Interleukin-13 Inhibitors Market Predicted to Surge During the Forecast Period (2025-2034) Due to Breakthrough Therapies in Atopic Dermatitis, Asthma, CRSwNP, and Others | DelveInsight
Sep 17, 2025 • PR Newswire
Sanofi's Brivekimig Improves Hidradenitis Suppurativa Symptoms in Phase 2a Study
Sep 17, 2025 • MarketScreener
Innate Pharma Reports First Half 2025 Business Update and Financial Results
Sep 17, 2025 • BioSpace
Sanofi: positive Phase 2a data for brivekimig
Sep 17, 2025 • MarketScreener
EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
Sep 17, 2025 • PharmiWeb
Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability
Sep 17, 2025 • Benzinga.com
AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
Sep 16, 2025 • BioSpace
AllRock Bio Announces $50 Million Series A to Advance Lead Clinical Program for Pulmonary Hypertension
Sep 16, 2025 • PR Newswire
Kymera initiated at Outperform on potential of lead skin drug
Sep 16, 2025 • Investing.com
GSK joins US investment spree with $30B planned for manufacturing, R&D
Sep 16, 2025 • FiercePharma
With Drug Picked Up From Sanofi, Startup AllRock Takes Aim at Two Severe Lung Diseases
Sep 16, 2025 • MedCity News
Kling Bio Validates its Proprietary B-Cell Technology for Rapid Response Against Emerging Viral Variants
Sep 9, 2025 • PR Newswire
Lucem Health announces new initiative to accelerate early detection of Type 1 Diabetes (T1D)
Sep 9, 2025 • Morningstar.com
With Asthma-Related ER Visits Increasing, AAFA Names 2025 Asthma Capitals
Sep 9, 2025 • Morningstar.com
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight
Sep 8, 2025 • PR Newswire UK
Alnylam Pharma rises after announcing $500 convertible bond offering
Sep 8, 2025 • Reuters
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Wayrilz™ (rilzabrutinib)
Sep 8, 2025 • Onco360 Oncology Pharmacy
Sanofi just upgraded at Morgan Stanley, here's why
Sep 8, 2025 • thefly.com
Asthma Market to Show Paltry Growth at a CAGR of 1.95% During the Forecast Period (2025-2034) | DelveInsight
Sep 8, 2025 • PR Newswire
The week in pharma: action, reaction and insight – week to September 5
Sep 7, 2025 • Pharma Letter
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
Sep 5, 2025 • Media Outreach
Sanofi's Eczema Drug Candidate Hits Main Goals in Late-Stage Trial
Sep 4, 2025 • MarketScreener
Sanofi's Amlitelimab Antibody Meets Primary Endpoints in Late-stage Study for Dermatitis
Sep 4, 2025 • MarketScreener
Sanofi says amlitelimab met primary and secondary endpoints in Coast 1 phase 3 study
Sep 4, 2025 • MarketScreener
Auto Injection, Ypsomed Settle Insulin Pen Patent Dispute
Sep 3, 2025 • Law360
Global drugmakers rush to boost US presence as tariff threat looms
Sep 3, 2025 • MarketScreener
ArcaScience raises $7M to transform drug development with AI-driven insights
Sep 3, 2025 • Tech.eu
Radiopharma’s big year: Interview with RadioMedix CEO Dr. Delpassand
Sep 3, 2025 • Labiotech UG
Thermo Fisher Scientific Completes Acquisition of Sanofi’s Ridgefield, New Jersey Site
Sep 2, 2025 • PharmiWeb
New Wave of ALS Therapies Signals Renaissance After Incremental Regression
Sep 2, 2025 • BioSpace
Thermo Fisher Scientific Completes Acquisition of Sanofi’s Ridgefield, New Jersey Site
Sep 2, 2025 • citybiz
Sanofi just upgraded at Deutsche Bank, here's why
Sep 2, 2025 • thefly.com
Sanofi: stock rises on Deutsche Bank upgrade
Sep 2, 2025 • MarketScreener
FDA green light for Sanofi's Wayrilz in ITP
Sep 1, 2025 • MarketScreener
Sanofi’s Wayrilz approved in USA for immune thrombocytopenia
Sep 1, 2025 • Pharma Letter
Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025
Sep 1, 2025 • Morningstar.com
Top 20 pharma companies shed $200 billion in value
Sep 1, 2025 • Pharma Letter
French Stocks Open Higher
Sep 1, 2025 • Trading Economics
Sanofi breaks new ground for BTK drugs with ITP approval
Sep 1, 2025 • pharmaphorum
Sanofi Gets US FDA Nod For Autoimmune Blood Disorder Pill
Aug 31, 2025 • MarketScreener
Chutes & Ladders—Sanofi snags CMO from BioMarin
Aug 29, 2025 • FierceBiotech
US FDA approves Sanofi's drug for a rare blood disorder
Aug 29, 2025 • MarketScreener
Sanofi Gets FDA Approval for Blood Disorder Treatment
Aug 29, 2025 • Morningstar.com
Press Release: Sanofi’s Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia
Aug 29, 2025 • Morningstar.com
Drugmakers Hail Early Wins in AI-Driven Transformation of Manufacturing
Aug 26, 2025 • BioSpace
Smart Insulin Pens & Pumps Market to Hit USD 14.6 Bn by 2035, Growing at 8.5% CAGR from 2025 | TMR
Aug 26, 2025 • EIN Presswire
Scribe Therapeutics to Demonstrate Scientific and Corporate Leadership at Upcoming Conferences
Aug 25, 2025 • PharmiWeb
Global Suppositories Market to Surpass USD 2.05 Billion by 2030 | MarketsandMarkets™
Aug 25, 2025 • MarketsandMarkets Research Pvt. Ltd.
US Rheumatologists Point to Difficult-to-Treat populations, Oral Delivery, and Novel Mechanisms as the Key Drivers of Future RA Treatment Evolution, According to Spherix Global Insights
Aug 25, 2025 • Spherix Global Insights
Crohn's Disease Market Projected to Grow at 4.3% CAGR (2020-2034), Driven by Improved Diagnosis, Pediatric Label Expansion, and New Second-line Therapies | DelveInsight
Aug 25, 2025 • PR Newswire
The Next Big Thing: 2 AI-Powered Healthcare Stocks Ready to Explode
Aug 23, 2025 • The Motley Fool
The Sanofi pipeline in 2025: Is the play-to-win strategy working?
Aug 22, 2025 • Labiotech.eu
Pediatric Asthma Treatment Market Anticipated to Grow at 0% CAGR Through 2029: Industry Report
Aug 22, 2025 • EIN Presswire
Thermo Fisher opens automated lab tools plant in North Carolina
Aug 22, 2025 • FierceBiotech
Orthobiologics Market to Reach USD 12.2 Billion by 2035, Driven by Rising Demand for Regenerative Therapies
Aug 22, 2025 • EIN Presswire
'They Didn't Believe Girls Could Bleed Like That': New Documentary Exposes Significant Gender Bias in Hemophilia Care
Aug 22, 2025 • EIN Presswire
Pneumococcal Infections Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15+ Companies and 20+ Therapies | DelveInsight
Aug 21, 2025 • DelveInsight Business Research LLP
Diabetes Care Drugs Market Projected to Witness a Growth of US $90.5 Billion by 2029 | The Business Research Company
Aug 21, 2025 • EIN Presswire
Gastric Cancer Therapy Market Size Worth $6.39 Billion by 2029 - Exclusive Report by The Business Research Company
Aug 21, 2025 • EIN Presswire
Inflexion Sells European LifeCare Group to European PE Firm
Aug 21, 2025 • Mergers & Acquisitions
Leaders Come Together to Advance the Industry at Veeva Summit
Aug 21, 2025 • MarketScreener
Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease
Aug 19, 2025 • prnasia.com
PD-1 Inhibitor Drugs Market to Reach USD 201.5 Bn by 2035, Expanding at 15.5% CAGR | TMR Analysis
Aug 19, 2025 • EIN Presswire
global monoclonal antibody therapeutics market
Aug 19, 2025 • PharmiWeb
Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Analysis Demonstrates 12+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
Aug 19, 2025 • DelveInsight Business Research LLP
Age-Related Macular Degeneration Market Set to Reach $15.4 Billion by 2032
Aug 19, 2025 • EIN Presswire
TSLP Inhibitors Market Set for Significant Growth During the Forecast Period (2025-2034) Driven by Breakthrough Therapies | DelveInsight
Aug 18, 2025 • PR Newswire UK
Digital Therapeutic Devices Market is Projected to Reach USD 40 Billion, with a Robust 16.88% CAGR Till 2035
Aug 18, 2025 • EIN Presswire
TSLP Inhibitors Market Set for Significant Growth During the Forecast Period (2025-2034) Driven by Breakthrough Therapies | DelveInsight
Aug 18, 2025 • PR Newswire
Self-Monitoring Blood Glucose Device Market is Poised to Growth USD 33.30 Billion by 2034 with Thriving CAGR of 11.44%
Aug 18, 2025 • EIN Presswire